Drugs / HG146
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04977167 | Jul 2023 → Dec 2024 | cancer, lymphoma | HitGen Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT03710915 | Jan 2019 → Sep 2022 | plasma cell myeloma, refractory plasma cell neoplasm | HitGen Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06781567 | Dec 2024 → Dec 2028 expected | adenoid cystic carcinoma, head and neck cancer | HitGen Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-05-07 | HitGen Inc. | Regulatory HitGen's Small Molecule IND Receives Approval by CFDA for Clinical Trials hitgen.com ↗
HitGen Ltd. announced that its novel small molecule Class I/IIb HDAC inhibitor HG146 (Category 1 of new chemical drug) received approval by Chinese Food and Drug Administration (CFDA) to begin the clinical trialsforMultiple Myeloma. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-05-07 | HitGen Inc. | HitGen's Small Molecule IND Receives Approval by CFDA for Clinical Trials hitgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HG146 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04977167 ↗ |
| Route | Oral | “subjects are administered orally HG146 every other day for two weeks” NCT03710915 ↗ |